WordPress database error: [Table 'thehealthcarenews_org_db.wp_ppress_sessions' doesn't exist]
SELECT * FROM wp_ppress_sessions WHERE session_key = '79c9c07da5978c3ca1bda1e35c01fbf5'

Curative Biotechnology Announces IMT504 License for Next Generation COVID-19 Vaccine Development Press "Enter" to skip to content

Curative Biotechnology Announces IMT504 License for Next Generation COVID-19 Vaccine Development

Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) stated today that it has expanded its previously announced licensing of IMT504, unique proprietary immunotherapy, and adjuvant, to cover the development of a next-generation COVID-19 vaccine. The vaccine will first be developed for the renal failure patient group by the company.

This new License, which uses IMT504 as an adjuvant on top of a proprietary protein vaccine, adds a second infectious disease program to Curative Biotech’s product development portfolio, which also includes a Metformin reformulation License from the National Eye Institute at the National Institutes of Health (NIH) to treat degenerative eye diseases and a novel monoclonal antibody/drug combination License from the National Cancer Institute at NIH to treat brain cancer.

It is becoming evident that the first COVID-19 vaccinations created did not work for everyone. People, who are really vulnerable, such as those with renal failure who require a kidney transplant or dialysis, are being left behind. We require tailored vaccinations for this immunocompromised patient population “Paul Michaels, Chairman, and President of Curative Biotech stated.Curative Biotech and Mid-Atlantic BioTherapeutics have decided to collaborate on the development of a next-generation COVID-19 vaccine to address the requirements of this vulnerable group.

The lack of a strong immune response to infections, including COVID-19, is a consequence of renal failure in general. This means that individuals with renal failure may receive a more severe form of COVID-19, increasing their chances of hospitalization or possibly death.Mid-Atlantic BioTherapeutics CEO Dr. David Horn added: “It is widely documented that kidney transplant recipients respond poorly to mRNA COVID-19 vaccinations. According to recent French statistics, even after four vaccination doses, many kidney transplant recipients had unsatisfactory outcomes.”

Be First to Comment

Leave a Reply

Your email address will not be published.